A Preliminary Study of Proton Therapy Combined with Cisplatin by Terakawa  A. et al.
A Preliminary Study of Proton Therapy Combined
with Cisplatin
著者 Terakawa  A., Ishii  K., Matsuyama  S.,
Kikuchi  Y., Ito  Y., Yasunaga  S., Tagawa 
A., Kawamura  T., Takahashi  Y., Hatori  Y.,
Hamada  N., Fujiki  K., Miura  Y., Yamazaki 
H., Funaki  Y., Itoh  N., Wada  S., Sera  K.
journal or
publication title
CYRIC annual report
volume 2010-2011
page range 46-48
year 2011
URL http://hdl.handle.net/10097/54238
 
 
46 
CYRIC Annual Report 2010-2011 
 
 
 
IV. 2.  A Preliminary Study of Proton Therapy Combined with Cisplatin 
 
 
 
Terakawa A.1,2, Ishii K.1,2, Matsuyama S.1, Kikuchi Y.1, Ito Y.1, Yasunaga S.1,  
Tagawa A.1, Kawamura T.1, Takahashi Y.1, Hatori Y.1, Hamada N.1, Fujiki K.1, Miura Y.1, 
 Yamazaki H.3, Funaki Y.3, Itoh N.4, Wada S.4, and Sera K.5 
 
1Department of Quantum Science and Energy Engineering, Tohoku University 
2Graduate School of Biomedical Engineering, Tohoku University 
3Cyclotron and Radioisotope Center, Tohoku University 
4School of Veterinary Medicine and Animal Sciences, Kitasato University 
5Cyclotron Center, Iwate Medical University 
 
 
 
A proton beam is expected to have small radiation effects on normal tissue in 
comparison to a photon beam because of its superior dose distribution, the so-called Bragg 
peak while a clinical proton beam generating a spread-out Bragg peak have about the same 
biological effects on tumor cells as an X-ray.  Thus, sensitization in proton therapy may 
provide significant therapeutic advantages over conventional radiotherapy.  
The chemotherapeutic agent Cisplatin (cis-diamminedichloro-platinum(II) : CDDP) 
not only inhibits tumor growth but also give rise to therapeutic enhancement when 
combined with radiotherapy1).  The aims of this study were to evaluate therapeutic 
enhancement for proton therapy combined with CDDP administration in a murine solid 
tumor model, and to investigate platinum concentration in the treated tumor by means of 
conventional and submilli PIXE analyses to study a relationship between the CDDP uptake 
and the enhanced anti-tumor effects caused by the combined treatment.  In this report, 
preliminary results of the CDDP-combined proton therapy and the PIXE analysis of the 
treated tumors are described. 
The experiment was performed using a proton therapy system2) at Cyclotron and 
Radioisotope Center (CYRIC), Tohoku University.  NFSa fibrosarcoma cells (5.0×106) 
were transplanted into both hind legs of C3H/He male mice aged 10-12 weeks old.  When 
tumor sizes reached a mean diameter of about 10 mm, CDDP was administered 
intraperitoneally to the mice at a single dose of 10 mg/kg.  For proton therapy alone, the 
tumors in the right hind legs received local proton irradiation without CDDP administration 
as a single dose of 15 or 30 Gy at a dose rate of 4 Gy/min using an irradiation field 20 mm 
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in diameter and a 20 mm SOBP.  When CDDP and proton therapy were combined, the 
tumors in the right hind legs were also irradiated locally with a single dose of 30 Gy 1 hour 
after CDDP administration.  The tumor diameters were measured after the treatments using 
a small animal CT-scanner (Clairvivo® CT, SIMAZU Co. Ltd., Japan) or Vernier calipers. 
The conventional PIXE analysis of the tumor tissue were performed using a PIXE 
analysis system3) at Nishina Memorial Cyclotron Center (NMCC), Japan Radioisotope 
Association.  The tumors were excised from the mice 6 hours after each treatment and 
frozen in powdered dry ice.  Sample preparation was done by means of a chemical ashing 
method.  The tumor samples were dissolved with nitric acid using a microwave oven. 
Indium solution (1000 ppm) was added to the samples as an internal standard element.  
The samples were irradiated using a 2.9 MeV proton beam from an AVF cyclotron at 
NMCC.  Two Si(Li) detectors were used to measure low and high X-ray energy regions 
separately.  A sheet of mylar 500 µm thickness was used as an absorber in the high X-ray 
energy measurement. 
Platinum distribution in the tumor tissue was investigated by means of submilli PIXE 
analysis at Tohoku University.  We obtained tissue sections by cutting the frozen tumors in 
a cryostat (-20°C), and mounted them on 4 mm thick polycarbonate films.  Thickness of 
the section was 250 µm.  The samples were stored at -80°C until the PIXE analyses. 
Elemental maps of the samples were obtained from beam scanning with a 3-MeV proton 
pencil beam.  The spot size of the proton beam was about 0.5 mm (FWHM).  Details of 
the submilli camera system have been described elsewhere4). 
Tumor volumes were calculated according to V=(6/p)abc, where a, b and c are three 
orthogonal diameters of the tumor.  Figure 1 shows time course of tumor volumes after 
each single treatment.  It is found that proton therapy combined with CDDP treatment 
showed the therapeutic enhancement significantly.  The effect of the combined treatment 
on tumor growth delay may be additive.  The conventional PIXE analysis of the tumor 
sample by the internal standard method resulted in the platinum concentration of 2.6±0.3 
ppm.  The submilli PIXE results showed that the platinum distribution in the tumor section 
appears to be almost uniform (Fig. 2), suggesting that CDDP reached hypoxic cell region as 
well as oxygenated cells in the tumor. 
In conclusion, the significant therapeutic enhancement was observed in proton 
therapy combined with CDDP treatment on the basis of the murine NFSa fibrosarcoma 
model.  The conventional PIXE analysis using the internal standard method showed that 
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the platinum concentration in the tumor inducing the therapeutic enhancement was 2.6±0.3 
ppm.  The submilli PIXE analysis of the tumor sections has revealed that CDDP 
distribution may be almost uniform in the tumor. 
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Figure 1.  Time course of the tumor volumes of proton therapy alone , CDDP treatment alone and the 
combined treatment. 
 
 
 
Figure 2.  Elemental maps obtained from the submilli PIXE of the tissue section of the CDDP-treated tumor 
(10 mg/kg). 
